← 返回

参与黑色素瘤荷瘤 Rag1 敲除小鼠过继性 T 细胞治疗中全身照射和白细胞介素-2 预处理方案的促肿瘤与抗肿瘤因素

英文原题:Pro- and Anti-Tumoral Factors Involved in Total Body Irradiation and Interleukin-2 Conditioning in Adoptive T Cell Therapy of Melanoma-Bearing Rag1 Knock-Out Mice.

查看英文原题

Pro- and Anti-Tumoral Factors Involved in Total Body Irradiation and Interleukin-2 Conditioning in Adoptive T Cell Therapy of Melanoma-Bearing Rag1 Knock-Out Mice.

PubMed 2022/12/02(内容时间) Cells Q2 · IF 6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

在过继性T细胞治疗(ACT)中,肿瘤特异性T细胞的转移与预处理方案并行,以提高治疗效果。预处理的目的是清除免疫抑制细胞,而后处理则增加稳态信号以改善输入T细胞的持久性。识别参与预处理方案的有利免疫学因素对于设计有效的ACT策略至关重要。

在此,我们利用小鼠黑色素瘤的ACT模型,评估了全身照射(TBI)与白细胞介素-2(IL-2)联合治疗的效果。使用缺乏内源性T细胞的Rag1敲除株,能够以更聚焦于转移T细胞的方式识别相关因素。

我们证明,尽管每种预处理均能改善治疗结果,但TBI/IL-2联合在ACT中并无叠加效应。虽然联合治疗增加了转移T细胞在淋巴组织和肿瘤组织中的频率,但与单独TBI治疗相比,这些细胞的活化强度降低。

值得注意的是,我们发现在TBI存在的情况下,IL-2治疗降低了瘤内树突状细胞的频率,而树突状细胞对T细胞活化至关重要。本研究为ACT中TBI/IL-2联合所涉及的免疫学事件提供了见解。

展开英文摘要原文

In adoptive T cell therapy (ACT), the transfer of tumor-specific T cells is paralleled by the conditioning regimen to increase therapeutic efficacy. Pre-conditioning depletes immune-suppressive cells and post-conditioning increases homeostatic signals to improve the persistence of administered T cells. Identifying the favorable immunological factors involved in a conditioning regimen is important to design effective strategies in ACT.

Here, by using an ACT model of murine melanoma, we evaluate the effect of the total body irradiation (TBI) and interleukin-2 (IL-2) treatment combination. The use of a Rag1 knock-out strain, which lacks endogenous T cells, enables the identification of factors in a way that focuses more on transferred T cells.

We demonstrate that the TBI/IL-2 combination has no additive effect in ACT, although each conditioning improves the therapeutic outcome. While the combination increases the frequency of transferred T cells in lymphoid and tumor tissues, the activation intensity of the cells is reduced compared to that of the sole TBI treatment.

Notably, we show that in the presence of TBI, the IL-2 treatment reduces the frequency of intra-tumoral dendritic cells, which are crucial for T cell activation. The current study provides insights into the immunological events involved in the TBI/IL-2 combination in ACT.

论文信息

作者
Kim SH、Go EM、Shin DH、Choi BK、Han C
单位
Immuno-Oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang 10408, Republic of Korea.South Korea
期刊
Cells2022 Dec 2
原文标识
PubMed 36497152 · DOI 10.3390/cells11233894